Deutsche Bank analyst George Hill maintains UnitedHealth Group (NYSE:UNH) with a Buy and lowers the price target from $564 to $555.
Deutsche Bank lowers UnitedHealth Group (NYSE:UNH) price target from $564 to $555 Read Post »
Bernstein analyst Lance Wilkes upgrades UnitedHealth Group (NYSE:UNH) from Market Perform to Outperform and raises the price target from $595 to $603.
Bernstein raises UnitedHealth Group (NYSE:UNH) price target from $595 to $603 Read Post »
UBS analyst Kevin Caliendo maintains UnitedHealth Group (NYSE:UNH) with a Neutral and raises the price target from $510 to $520.
UBS raises UnitedHealth Group (NYSE:UNH) price target from $510 to $520 Read Post »
Baird analyst David Rescott initiates coverage on Boston Scientific (NYSE:BSX) with a Outperform rating and announces Price Target of $59.
Baird announces Boston Scientific (NYSE:BSX) Price Target of $59 Read Post »
Truist Financial analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $60 to $61.
Truist Financial raises Boston Scientific (NYSE:BSX) price target from $60 to $61 Read Post »
Citigroup analyst Joanne Wuensch maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and raises the price target from $317 to $400.
Citigroup raises Intuitive Surgical (NASDAQ:ISRG) price target from $317 to $400 Read Post »
RBC Capital analyst Shagun Singh maintains Intuitive Surgical (NASDAQ:ISRG) with a Outperform and raises the price target from $309 to $355.
RBC Capital raises Intuitive Surgical (NASDAQ:ISRG) price target from $309 to $355 Read Post »
Baird analyst Mike Polark initiates coverage on Intuitive Surgical (NASDAQ:ISRG) with a Outperform rating and announces Price Target of $377.
Truist Financial analyst Richard Newitter maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and raises the price target from $347 to $400.
JPMorgan analyst Lisa Gill maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $125 to $114.
JPMorgan lowers CVS Health (NYSE:CVS) price target from $125 to $114 Read Post »
CVS Health (NYSE:CVS) said Wednesday it maintained its 2023 guidance, including adjusted per-share earnings of $8.50 to $8.70. Analysts surveyed by Capital IQ expect $8.63. The company said it reaffirmed its cash flow operations outlook range of $12.50 billion to $13.50 billion and continues to expect more than half of 2023 earnings in the second half of 2023, with Q3 earnings being modestly higher than in Q4.
CVS Health (NYSE:CVS) Maintains 2023 Outlook Read Post »
Bernstein analyst Lee Hambright maintains Intuitive Surgical (NASDAQ:ISRG) with a Outperform and raises the price target from $350 to $365.
Bernstein raises Intuitive Surgical (NASDAQ:ISRG) price target from $350 to $365 Read Post »